Related coverage linked through entity extraction aliases.
May 20, 2026
An experimental study found remote ischemic conditioning protected the heart during anthracycline treatment in tumor-bearing mice without reducing antitumor efficacy. The work supports the ongoing RESILIENCE clinical trial in cancer patients.
May 12, 2026
Phase 1 data in 17 adults with Friedreich's ataxia cardiomyopathy showed AAVrh.10hFXN (LX2006) was generally well tolerated and showed signs of biological activity. The gene therapy is being advanced into a larger trial.
May 05, 2026
CVRx announced first-patient enrollment in the BENEFIT-HF trial, a 2,500-patient heart failure study across about 150 U.S. and German centers. The trial will evaluate all-cause mortality and heart failure decompensation events through 2032.
May 04, 2026
More cancer survivors are living long enough to face lasting cardiovascular effects of treatment. Cardio-oncology clinics are managing heart failure, valvular disease and radiation-related heart disease.
May 04, 2026
Research in the United Kingdom found that preventing type 2 diabetes cut care-related greenhouse gas emissions by about 67%, while well-controlled disease was linked to 21% lower emissions than uncontrolled diabetes.
Apr 28, 2026
Compass Therapeutics reported mixed Phase 2/3 data for tovecimig in biliary tract cancer and plans to meet with the FDA for a BLA discussion. The study met its primary ORR endpoint (17% vs 5%), while PFS and OS data are due late this quarter.
Apr 24, 2026
Two studies found cardiac MRI-derived biomarkers may improve heart failure risk assessment. Epicardial adipose tissue index was linked to HFpEF risk, while imaging-derived SvO2 predicted hospitalization and death.
Apr 22, 2026
Novartis reported 2025 sales of $54.5 billion, up 8%, while earnings per share rose 15% to $8.98. Amarin reported fiscal 2025 revenue of $213.6 million, down 6.5%, and narrowed its net loss per share to $0.09 from $0.20.
Apr 18, 2026
A multicenter retrospective cohort study of 17 patients with type 2 diabetes and end-stage renal disease found injectable semaglutide was associated with descriptive changes in glycemic control and body weight. No cardiovascular deaths, nonfatal myocardial infarctions, or nonfatal strokes were observed during follow-up.
Apr 15, 2026
A study found seniors with screening-detected atrial fibrillation had a roughly threefold higher risk of heart failure. Heart failure was often diagnosed within six months.
Apr 03, 2026
Analysis of 585 clinical trials reveals region is the primary driver of risk variation, with North America showing 29% higher screen failure rates. Heart failure trials show severe underrepresentation, with only 14.5% of participants from outside Europe and North America despite Asia having 50% of global heart failure cases. Central monitoring methods and representativeness indices are proposed to address these disparities.
Apr 02, 2026
Phase 3 trial results show seralutinib missed its primary endpoint in PAH but showed benefit in advanced disease subgroups. Meanwhile, Winrevair demonstrated significant reductions in pulmonary vascular resistance in heart failure-related pulmonary hypertension in a Phase 2 study.
Apr 02, 2026
20/20 BioLabs has licensed ROKIT Healthcare's chronic kidney disease prediction algorithm for its longevity platform, expanding from inflammation tracking to specific risk detection. The technology will be integrated into the company's OneTest for Longevity program, with potential applications for improving outcomes in regenerative treatments. The agreement includes revenue sharing and could lead to exclusive commercialization rights for ROKIT in East Asian markets.
Apr 01, 2026
A study of over 600,000 patients reveals GLP-1 drugs may reduce addiction across multiple substances, with 50% fewer substance-related deaths and significant reductions in overdoses and hospitalizations. The drugs work by dampening dopamine signaling in brain reward centers. Researchers are exploring broader applications for these medications beyond diabetes and obesity treatment.
Mar 31, 2026
A study finds nearly half of melanoma patients receiving BRAF or MEK inhibitors develop hypertension or cardiac dysfunction. Moderate to severe cardiac issues appear within 4 weeks and only in patients with medium or higher baseline risk. Higher baseline NT-proBNP levels are associated with increased cardiac dysfunction risk.
Mar 30, 2026
Mavacamten significantly reduces heart obstruction in adolescents with hypertrophic cardiomyopathy, with patients experiencing a 48.5 mm Hg drop in blockage compared to minimal change in placebo groups. The drug also lowered blood markers indicating heart damage and showed promise in slowing disease progression. Separate real-world data confirms mavacamten's effectiveness as monotherapy across diverse patient populations.
Mar 26, 2026
A new study of over 246,000 heart disease patients shows the shingles vaccine reduces major cardiovascular events by 46% and death by 61% within one year. The protective effects are comparable to quitting smoking and support existing vaccine recommendations for adults over 50. The findings will be presented at the American College of Cardiology's annual meeting.
Mar 18, 2026
New research shows home-based exercise reduces cognitive impairment during chemotherapy, while cardio-oncology programs monitor and minimize heart complications from cancer treatments that pose cardiovascular risks to survivors.
Mar 18, 2026
CellProthera plans to launch a Phase III trial of its ProtheraCytes stem cell therapy for heart failure patients in Q1 2027, enrolling 300-400 patients across 50 sites. The company acquired a transendocardial catheter from Celyad Oncology for €5 million to enable precise delivery of the therapy.
Mar 14, 2026
New research demonstrates RNA therapies can enhance heart regeneration after injury, while RNA biomarkers improve prediction of cardiovascular complications in chronic kidney disease patients.
